Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Autoinjectors Market to Grow from USD 127.30 Billion in 2026 to USD 300.46 Billion by 2031, at a CAGR of 18.7% – MarketsandMarkets™

globenewswire.com
BDX Becton, Dickinson and Company is mentioned as a major participant in the consolidated autoinjectors market, focusing on technological innovation and regulatory approvals. The article does not provide specific sentiment towards the company's performance. LLY Eli Lilly and Company is listed as a major participant in the autoinjectors market. The article highlights the company's involvement in a growing market driven by chronic diseases and technological advancements, but offers no specific sentiment. ABBV AbbVie is identified as a key player in the autoinjectors market. The article notes its participation in a growing sector driven by chronic diseases and innovation, without providing specific sentiment for the company. AMGN Amgen is mentioned as a major participant in the autoinjectors market. The article discusses the market's growth drivers and competitive landscape, but does not offer specific sentiment for Amgen. JNJ Johnson & Johnson is listed as a major participant in the autoinjectors market. The article focuses on market trends and growth, without providing specific sentiment for the company. HALO Halozyme is identified as a participant in the autoinjectors market. The article mentions its role in a growing industry driven by technological advancements and increased adoption of self-administered medicines, but provides no specific sentiment.

Autoinjectors Market to Grow from USD 127.30 Billion in 2026 to USD 300.46 Billion by 2031, at a CAGR of 18.7% – MarketsandMarkets™ Delray Beach, FL, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global autoinjectors market will grow from USD 127.30 billion in 2026 to USD 300.46 billion by 2031, at a CAGR of 18.7% during the forecast period. Market growth is fueled by the rising prevalence of chronic and autoimmune diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis, increasing regulatory approvals for autoinjector-based therapies, and growing adoption of self-administered medicines for long-term treatment. Favorable reimbursement policies, government initiatives, and continuous technological advancements in smart, connected, and reusable autoinjector platforms are further accelerating market expansion worldwide.

Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

Key Market Highlights

Why This Market Matters

The increasing burden of chronic and autoimmune diseases worldwide is driving strong demand for convenient and reliable self-injection technologies. As biologic therapies become the standard of care for conditions such as diabetes, rheumatoid arthritis, multiple sclerosis, and obesity, autoinjectors are enabling patients to safely administer medications outside traditional healthcare settings. At the same time, innovations in smart autoinjectors, digital adherence monitoring, reusable platforms, and connected healthcare ecosystems are improving treatment compliance, patient convenience, and overall therapeutic outcomes while reducing dependence on hospital-based care.

Market Overview

The autoinjectors market is undergoing significant transformation as manufacturers move beyond conventional disposable injection devices toward connected, reusable, and digitally enabled drug delivery platforms. Healthcare providers, home-care settings, and ambulatory care centers are increasingly prioritizing patient adherence, ease of administration, and real-time treatment monitoring. Although challenges remain in delivering high-viscosity biologics and ensuring compatibility across diverse formulations, continued product innovation, regulatory support, and expanding biologics adoption are expected to sustain long-term market growth.

Analyst Perspective

The future of the autoinjectors industry lies in intelligent drug delivery systems that combine connected devices, digital health platforms, adherence monitoring, and patient-centric design. Manufacturers are increasingly investing in Bluetooth-enabled autoinjectors, reusable delivery platforms, hidden-needle technologies, and needle-free injection systems to improve user experience and long-term treatment adherence. As personalized medicine and home-based healthcare continue expanding, companies integrating digital therapeutics with advanced drug delivery technologies are expected to strengthen their competitive position over the coming years.

Speak to Our Analyst - Get Custom Insights: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=173991724

Segment Analysis

By type, the finished formulation autoinjectors segment accounted for the largest market share in 2025 owing to ready-to-use formats, ease of administration, lower dosing errors, and greater patient convenience. Growing adoption of biologics and specialty pharmaceuticals continues to support segment expansion.

By actuation mechanism, mechanical (spring-based) autoinjectors dominated the market due to their cost-effectiveness, established manufacturing processes, reliability, and minimal training requirements.

By route of administration, the subcutaneous segment is expected to witness the fastest growth during the forecast period, driven by lower pain perception, suitability for home-based care, and increasing use of biologic therapies.

By therapy area, rheumatoid arthritis accounted for the largest market share, supported by the growing use of biologic therapies requiring regular self-administration.

Regional Analysis

The Asia Pacific region is projected to register the highest CAGR during the forecast period, driven by rising healthcare expenditure, growing diabetic and elderly populations, increasing prevalence of chronic diseases, expanding healthcare infrastructure, and improving access to biologic therapies. Government initiatives supporting affordable healthcare and growing awareness regarding self-administered therapies are expected to further accelerate adoption across the region.

Key Industry Trends

Competitive Landscape

The autoinjectors market is consolidated, with leading companies focusing on technological innovation, regulatory approvals, strategic collaborations, and biologic drug partnerships to strengthen their market positions. Major participants include Becton, Dickinson and Company (US), SHL Medical (Switzerland), Ypsomed AG (Switzerland), Novo Nordisk (Denmark), Eli Lilly and Company (US), AbbVie (US), Amgen (US), Sanofi (France), AstraZeneca (UK), Owen Mumford (UK), Phillips-Medisize (US), Halozyme (US), GSK (UK), and Johnson & Johnson (US). While global leaders dominate through strong manufacturing capabilities and established distribution networks, emerging companies continue introducing innovative and cost-effective solutions that enhance competition across the market.

Related Reports

Pharmaceutical Drug Delivery Market

Wearable Injectors Market